Open main menu

Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines (Q61909688)

clinical trial
edit
Language Label Description Also known as
English
Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines
clinical trial

    Statements

    KEd (English)
    0 references
    0 references
    0 references
    Phase 2 Study of Carfilzomib + Elotuzumab + Dexamethasone for Relapsed or Progressed Multiple Myeloma After 1-3 Prior Treatment Lines (English)
    0 references
    7 August 2017
    0 references
    21 June 2020
    0 references
    40
    0 references
    18 year
    0 references
    74 year
    0 references

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit